Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.

Douglas G Johns Louis-Charles Campeau Puja BankaAn BautmansTjerk BuetersElisabetta Bianchi Danila BrancaPaul G BulgerInne CrevecoeurFa-Xiang DingRobert M GarbaccioErik D GuetschowYan GuoSookhee N HaJennifer M JohnstonHubert JosienEunkyung A KauhKenneth A KoeplingerJeffrey T KuetheEseng LaiChristine L LanningAnita Y H LeeLi LiAnilkumar G NairEdward A O'NeillS Aubrey StochDavid A ThaisrivongsThomas J TuckerPetr VachalKristien van DyckFrederic P VanhoutteBram VolckaertDennis G WolfordAndy XuTian ZhaoDan ZhouSusan ZhouXiaohong ZhuHratch J ZokianAbbas WaljiHarold B Wood

Published in: Circulation (2023)

This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.

Keyphrases

low density lipoprotein
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
binding protein
bioinformatics analysis
chronic kidney disease
patient reported outcomes
dna binding
climate change
transcription factor